GW Henssler & Associates Ltd. increased its position in shares of GlaxoSmithKline PLC (NYSE:GSK) by 7.3% during the second quarter, Holdings Channel reports. The fund owned 202,286 shares of the pharmaceutical company’s stock after buying an additional 13,694 shares during the period. GW Henssler & Associates Ltd.’s holdings in GlaxoSmithKline PLC were worth $8,723,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Proficio Capital Partners LLC boosted its position in GlaxoSmithKline PLC by 16.1% in the second quarter. Proficio Capital Partners LLC now owns 3,301 shares of the pharmaceutical company’s stock worth $135,000 after buying an additional 457 shares during the period. Checchi Capital Advisers LLC boosted its position in GlaxoSmithKline PLC by 3.6% in the second quarter. Checchi Capital Advisers LLC now owns 29,989 shares of the pharmaceutical company’s stock worth $1,293,000 after buying an additional 1,055 shares during the period. Wrapmanager Inc. boosted its position in GlaxoSmithKline PLC by 19.3% in the second quarter. Wrapmanager Inc. now owns 37,499 shares of the pharmaceutical company’s stock worth $1,617,000 after buying an additional 6,056 shares during the period. Conning Inc. boosted its position in GlaxoSmithKline PLC by 354.1% in the second quarter. Conning Inc. now owns 27,090 shares of the pharmaceutical company’s stock worth $1,168,000 after buying an additional 21,125 shares during the period. Finally, Trillium Asset Management LLC boosted its position in GlaxoSmithKline PLC by 3.9% in the second quarter. Trillium Asset Management LLC now owns 72,562 shares of the pharmaceutical company’s stock worth $3,129,000 after buying an additional 2,700 shares during the period. 8.99% of the stock is currently owned by institutional investors.

GlaxoSmithKline PLC (NYSE:GSK) opened at 39.24 on Thursday. The company has a market cap of $95.90 billion, a PE ratio of 37.95 and a beta of 1.03. GlaxoSmithKline PLC has a 52-week low of $37.20 and a 52-week high of $44.58. The company has a 50-day moving average of $41.41 and a 200 day moving average of $41.86.

GlaxoSmithKline PLC (NYSE:GSK) last released its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.02. The firm had revenue of $9.36 billion during the quarter, compared to the consensus estimate of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. Equities research analysts predict that GlaxoSmithKline PLC will post $2.85 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Stockholders of record on Friday, August 11th will be paid a dividend of $0.491 per share. The ex-dividend date is Wednesday, August 9th. This represents a $1.96 annualized dividend and a dividend yield of 5.01%. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is presently 197.00%.

TRADEMARK VIOLATION WARNING: “GW Henssler & Associates Ltd. Buys 13,694 Shares of GlaxoSmithKline PLC (GSK)” was originally reported by Daily Political and is the property of of Daily Political. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/08/17/gw-henssler-associates-ltd-buys-13694-shares-of-glaxosmithkline-plc-gsk.html.

A number of research analysts have recently issued reports on the stock. TheStreet cut shares of GlaxoSmithKline PLC from a “b” rating to a “c+” rating in a research note on Wednesday, July 26th. Citigroup Inc. reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Thursday, July 27th. BidaskClub cut shares of GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a research note on Monday, July 24th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Monday, July 24th. Finally, Zacks Investment Research cut shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, July 21st. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $44.67.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.